Novel Insights into Glioblastoma and Brain Metastases

Dear Colleagues,

Glioblastoma is an aggressive grade IV brain tumor leading to severe fatalities globally. Moreover, several cancers lead to brain metastasis which is a major cause of mortality. Tackling these conditions has several challenges, with the most important being the blood–brain barrier (BBB) permeability. Significant research is required to overcome these challenges. With surgery and radiation therapy being the major treatment strategy for brain tumors, intensive research has also been conducted on chemotherapies. Targeted therapies are currently being developed with beneficial effects in cancers such as colorectal, breast, lung, and melanoma. Radiation therapy has also proven to be quite successful against brain metastasis. Thus, in this Special Issue, we invite you to contribute your work concerning glioblastoma, novel insights into its treatment and management, and different cancers leading to brain metastasis. This Special Issue aims to highlight all types of work, such as clinical, pre-clinical, translational, and basic research. We invite both original research articles and review articles in this Special Issue. This critical topic would appeal to a number of scientists and clinicians in the field. The articles may include (but are not limited to) treatment, management, diagnosis, clinical trials, and molecular insights for glioblastoma and brain metastasis caused by different cancers such as breast, melanoma, renal, lung, colorectal, etc.

Prof. Dr. Sanjay K. Srivastava
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.